Michael Doe's Album: Wall Photos
Growing at an
annualized rate of over 35%, the large volume wearable injectors market for
delivery of non-insulin drugs, claims Roots Analysis
Over the years, a rise in
preference for self-administrable drugs / therapies has resulted in an
increasing demand for user-friendly drug delivery solutions that are not only
safe and efficient, but also promote therapy adherence
London
Roots Analysis has announced the addition of “Large Volume Wearable
Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous
Delivery Devices” report
to its list of offerings.
The wide-spread prevalence of
chronic diseases has compelled drug developers to innovate and design better, more advanced healthcare solutions.
Large volume wearable injectors were developed to specifically address certain
challenges associated with the administration of high volume formulations, viscous drug solutions and cater
to frequent dosing requirements of patients suffering from chronic health
conditions.
To order this 500+ page report, which features 175+ figures and 200+
tables, please visit –
https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html
Key
Market Insights
More than 25 large volume wearable injectors are
presently available / under development for the administration of drugs,
excluding insulin
Over 45% of the abovementioned
devices are capable of delivering bolus doses, followed by devices designed for
continuous dosing at pre-programmed rates (15 %). These devices are powered by
a diverse variety of actuation mechanisms, including rotary pumps, cells / expanded
batteries, springs, osmotic pressure and liquefied gas. It is worth noting that
over 15+ known drug-device combinations are commercialized / under development.
For insulin delivery alone, there are 30+ large
volume wearable injectors available / under development
It is worth highlighting that
nearly 40% of the abovementioned devices presently use advanced algorithms in
order to automate the delivery of insulin, based on integrated continuous blood
glucose monitoring systems. Of these, majority (23%) use the hybrid closed loop
system. Over 80% of such devices have special connectivity features that enable
better dosage monitoring.
More than 200 biologics / small molecule drugs
were identified as likely products to be developed in combination with large
volume wearable injectors
The report provides insights on
over 800 marketed drugs / therapies and pipeline candidates, assessing the
likelihood of whether they can be developed in combination with large volume
wearable injectors. The analysis takes into consideration current phase of
development of the drug, its dosage, dose concentration, route of
administration, type of dose and information on drug sales (for marketed drugs).
Nearly 90 partnerships
have been signed by developers of large volume wearable injectors between 2015
and 2020 (till March)
It is worth noting that more than
55% deals were established post 2017, indicating an increase in the partnership
activity within this domain. Majority of partnership deals were product /
technology integration agreements (29%), followed by deals focused on product
development and commercialization (23%), mergers and acquisitions (12%), and
product distribution (12%).
North America and Europe are anticipated to capture
over 60% of the market share, in terms of revenues generated from sales of non-insulin
drug delivery devices, in 2030
By 2030, 46% of revenues are
expected to be generated from the sales of large volume wearable injectors
intended for the treatment of neurological disorders, followed by products for
oncological disorders (27%), cardiovascular disorders (25%) and infectious
diseases (2%).
The large volume wearable
injectors market for insulin is anticipated to be worth over USD 2.7 billion by
2030
North America presently dominates
the global insulin market, consequently the region is expected to capture the
majority share (50%) in terms of revenues from wearable injector sales. It is
worth highlighting that the market in Asia-pacific is anticipated to grow at a
relatively faster pace.
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/238/request-sample.html
Key
Questions Answered
§
Who are the leading developers of large volume wearable devices?
§
What are the prevalent trends within the large volume wearable
injectors market?
§
Which drug candidates are suited for delivery via large volume
wearable injectors?
§
Who are the key contract service providers in this domain?
§
What are the various regulatory guidelines issued for medical
devices across different regions?
§
How is the current and future market opportunity likely to be
distributed across key market segments?
The financial opportunity within the large volume wearable
injectors market (for delivery of non-insulin and insulin drugs) has
been analyzed across the following segments:
§ Type
of Device
§
Patch Pump / Injectors
§
Infusion Pump / Injectors
§ Product
Usability
§
Disposable
§
Re-usable
§ Therapeutic
Area (for non-insulin drugs)
§
Neurological Disorders
§
Cardiovascular Disorders
§
Oncological Disorders
§
Infectious Disorders
§
Key geographical regions
§
North America
§
Europe
§
Asia Pacific and Rest of the World
The research includes detailed profiles of key players (listed
below); each profile features an overview of the company, its financial
information (if available),
a description of the product(s) offered, details of recent developments related
to large volume wearable injection devices and an informed future outlook.
§
Becton Dickinson
§
Bespak (subsidiary of Consort Medical)
§
CeQur
§
Debiotech
§
Eli Lilly
§
Enable Injections
§
Insulet
§
Medtronic
§
PharmaSens
§
Roche
§
SOOIL Development
§
Sonceboz
§
Sensile Medical (acquired by Gerresheimer)
§
SteadyMed Therapeutics (acquired by United Therapeutics)
§
Tandem Diabetes Care
§
Weibel CDS (acquired by SHL Medical)
§
West Pharmaceutical Services
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html[Jasparam1]
You may also be interested in the following titles:
1.
Microneedles and
Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and
Other Mechanisms) Market, 2019-2030 [COVID-19 Series]
2.
Global Autoinjectors
Market (3rd Edition), 2020-2030
3.
Prefilled Syringes
Market (5th Edition), 2020-2030
About Roots
Analysis
Roots Analysis is
one of the fastest growing market research companies, sharing fresh and
independent perspectives in the bio-pharmaceutical industry. The in-depth
research, analysis and insights are driven by an experienced leadership team
which has gained many years of significant experience in this sector. If you’d
like help with your growing business needs, get in touch at
info@rootsanalysis.com
Contact Information
Roots Analysis Private
Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter
- https://twitter.com/RootsAnalysis
[Jasparam1]Arun
to assist.
The link name shows large volume wearable injectors,
even on the website.
annualized rate of over 35%, the large volume wearable injectors market for
delivery of non-insulin drugs, claims Roots Analysis
Over the years, a rise in
preference for self-administrable drugs / therapies has resulted in an
increasing demand for user-friendly drug delivery solutions that are not only
safe and efficient, but also promote therapy adherence
London
Roots Analysis has announced the addition of “Large Volume Wearable
Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous
Delivery Devices” report
to its list of offerings.
The wide-spread prevalence of
chronic diseases has compelled drug developers to innovate and design better, more advanced healthcare solutions.
Large volume wearable injectors were developed to specifically address certain
challenges associated with the administration of high volume formulations, viscous drug solutions and cater
to frequent dosing requirements of patients suffering from chronic health
conditions.
To order this 500+ page report, which features 175+ figures and 200+
tables, please visit –
https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html
Key
Market Insights
More than 25 large volume wearable injectors are
presently available / under development for the administration of drugs,
excluding insulin
Over 45% of the abovementioned
devices are capable of delivering bolus doses, followed by devices designed for
continuous dosing at pre-programmed rates (15 %). These devices are powered by
a diverse variety of actuation mechanisms, including rotary pumps, cells / expanded
batteries, springs, osmotic pressure and liquefied gas. It is worth noting that
over 15+ known drug-device combinations are commercialized / under development.
For insulin delivery alone, there are 30+ large
volume wearable injectors available / under development
It is worth highlighting that
nearly 40% of the abovementioned devices presently use advanced algorithms in
order to automate the delivery of insulin, based on integrated continuous blood
glucose monitoring systems. Of these, majority (23%) use the hybrid closed loop
system. Over 80% of such devices have special connectivity features that enable
better dosage monitoring.
More than 200 biologics / small molecule drugs
were identified as likely products to be developed in combination with large
volume wearable injectors
The report provides insights on
over 800 marketed drugs / therapies and pipeline candidates, assessing the
likelihood of whether they can be developed in combination with large volume
wearable injectors. The analysis takes into consideration current phase of
development of the drug, its dosage, dose concentration, route of
administration, type of dose and information on drug sales (for marketed drugs).
Nearly 90 partnerships
have been signed by developers of large volume wearable injectors between 2015
and 2020 (till March)
It is worth noting that more than
55% deals were established post 2017, indicating an increase in the partnership
activity within this domain. Majority of partnership deals were product /
technology integration agreements (29%), followed by deals focused on product
development and commercialization (23%), mergers and acquisitions (12%), and
product distribution (12%).
North America and Europe are anticipated to capture
over 60% of the market share, in terms of revenues generated from sales of non-insulin
drug delivery devices, in 2030
By 2030, 46% of revenues are
expected to be generated from the sales of large volume wearable injectors
intended for the treatment of neurological disorders, followed by products for
oncological disorders (27%), cardiovascular disorders (25%) and infectious
diseases (2%).
The large volume wearable
injectors market for insulin is anticipated to be worth over USD 2.7 billion by
2030
North America presently dominates
the global insulin market, consequently the region is expected to capture the
majority share (50%) in terms of revenues from wearable injector sales. It is
worth highlighting that the market in Asia-pacific is anticipated to grow at a
relatively faster pace.
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/238/request-sample.html
Key
Questions Answered
§
Who are the leading developers of large volume wearable devices?
§
What are the prevalent trends within the large volume wearable
injectors market?
§
Which drug candidates are suited for delivery via large volume
wearable injectors?
§
Who are the key contract service providers in this domain?
§
What are the various regulatory guidelines issued for medical
devices across different regions?
§
How is the current and future market opportunity likely to be
distributed across key market segments?
The financial opportunity within the large volume wearable
injectors market (for delivery of non-insulin and insulin drugs) has
been analyzed across the following segments:
§ Type
of Device
§
Patch Pump / Injectors
§
Infusion Pump / Injectors
§ Product
Usability
§
Disposable
§
Re-usable
§ Therapeutic
Area (for non-insulin drugs)
§
Neurological Disorders
§
Cardiovascular Disorders
§
Oncological Disorders
§
Infectious Disorders
§
Key geographical regions
§
North America
§
Europe
§
Asia Pacific and Rest of the World
The research includes detailed profiles of key players (listed
below); each profile features an overview of the company, its financial
information (if available),
a description of the product(s) offered, details of recent developments related
to large volume wearable injection devices and an informed future outlook.
§
Becton Dickinson
§
Bespak (subsidiary of Consort Medical)
§
CeQur
§
Debiotech
§
Eli Lilly
§
Enable Injections
§
Insulet
§
Medtronic
§
PharmaSens
§
Roche
§
SOOIL Development
§
Sonceboz
§
Sensile Medical (acquired by Gerresheimer)
§
SteadyMed Therapeutics (acquired by United Therapeutics)
§
Tandem Diabetes Care
§
Weibel CDS (acquired by SHL Medical)
§
West Pharmaceutical Services
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html[Jasparam1]
You may also be interested in the following titles:
1.
Microneedles and
Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and
Other Mechanisms) Market, 2019-2030 [COVID-19 Series]
2.
Global Autoinjectors
Market (3rd Edition), 2020-2030
3.
Prefilled Syringes
Market (5th Edition), 2020-2030
About Roots
Analysis
Roots Analysis is
one of the fastest growing market research companies, sharing fresh and
independent perspectives in the bio-pharmaceutical industry. The in-depth
research, analysis and insights are driven by an experienced leadership team
which has gained many years of significant experience in this sector. If you’d
like help with your growing business needs, get in touch at
info@rootsanalysis.com
Contact Information
Roots Analysis Private
Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
- https://twitter.com/RootsAnalysis
[Jasparam1]Arun
to assist.
The link name shows large volume wearable injectors,
even on the website.